REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer

被引：0
|
作者：
Klajer, E. [1 ]
Jary, M. [1 ,2 ]
Borg, C. [1 ,2 ]
Kim, S. [1 ,2 ,3 ]
Vernerey, D. [2 ,3 ]
Henriques, J. [3 ]
N'Guyen, T. [1 ]
Nasri, M. [1 ]
Almotlak, H. [1 ]
Babre, J. [1 ]
Meurisse, A.
Fratte, S. [4 ]
Fein, F. [5 ]
Calcagno, F. [1 ]
Chanut, L.
Spehner, L. [2 ]
Rebucci-Peixoto, M. [6 ]
Vienot, A. [1 ,2 ]
机构：
[1] Univ Hosp Besancon, Dept Med Oncol, Besancon, France
[2] Univ Bourgogne Franche Comte, Interact Hote Greffon Tumeur Ingn Cellulaire & Ge, INSERM, EFS BFC,UMR1098,RIGHT, Besancon, France
[3] Univ Hosp Besancon, Methodol & Qual Life Oncol Unit, Besancon, France
[4] Nord Franche Comte Hosp, Dept Med Oncol, Besancon, France
[5] Univ Hosp Besancon, Dept Gastroenterol, Besancon, France
[6] Univ Hosp Besancon, Ctr Invest Clin, CIC 1431, Besancon, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
509TiP
引用
收藏
页码：S581 / S581
页数：1
相关论文
共 50 条
  • [1] Safety analysis and preliminary clinical results of REPROGRAM-01 phase II study evaluating regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
    Borg, C.
    Klajer, E.
    El Kaddissi, A.
    Ghiringhelli, F.
    Kim, S.
    Vernerey, D.
    Henriques, J.
    Nguyen, T.
    Meurisse, A.
    Fratte, S.
    Fein, F.
    Spehner, L.
    Rebucci-Peixoto, M.
    Vienot, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S115 - S115
  • [2] REPROGRAM-02: A phase II-III study evaluating an induction treatment with regorafenib and metronomic chemotherapy before the second line chemotherapy in metastatic colorectal cancer
    Vienot, Angelique
    Kim, Stefano
    Klajer, Elodie
    Vernerey, Dewi
    Ghiringhelli, Francois
    Tournigand, Christophe
    Cohen, Romain
    Husson, Stephanie
    Desrame, Jerome
    Bachet, Jean-Baptiste
    Benmaziane, Asmahane
    Soularue, Emilie
    Bouche, Olivier
    Gallois, Claire
    Assenat, Eric
    Meurisse, Aurelia
    Rebucci-Peixoto, Magali
    Borg, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy
    Kudo, Toshihiro
    Kato, Takeshi
    Kagawa, Yoshinori
    Sakai, Daisuke
    Satoh, Taroh
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [4] Phase II Dose Titration Study of Regorafenib for Patients With Unresectable Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 18 - 19
  • [5] Phase II study on starting with reduced dose of regorafenib for metastatic colorectal cancer after standard chemotherapy
    Ota, Hirofumi
    Kagawa, Yoshinori
    Ohta, Katsuya
    Miyazaki, Susumu
    Hamabe, Atsushi
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Yamamoto, Hirofumi
    Doki, Yuichiro
    Mori, Masaki
    CANCER SCIENCE, 2018, 109 : 307 - 307
  • [6] Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
    Lin, Chun-Yu
    Lin, Tseng-Hsi
    Chen, Chou-Chen
    Chen, Ming-Cheng
    Chen, Chou-Pin
    PLOS ONE, 2018, 13 (01):
  • [7] Phase II study of metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with refractory metastatic colorectal cancer (MCRC).
    Moiseyenko, V.
    Chubenko, V.
    Protsenko, S.
    Mikhalichenko, T.
    Moiseyenko, F.
    Brezhnev, N.
    Moiseyenko, A.
    Kornilov, A.
    Zueva, E.
    Gorchakova, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy
    Kudo, T.
    Kato, T.
    Kagawa, Y.
    Murata, K.
    Ohta, H.
    Noura, S.
    Hasegawa, J.
    Tamagawa, H.
    Ohta, K.
    Ikenaga, M.
    Miyazaki, S.
    Komori, T.
    Nishimura, J.
    Hata, T.
    Matsuda, C.
    Satoh, T.
    Mizushima, T.
    Yamamoto, H.
    Doki, Y.
    Mori, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] NON-RANDOMIZED PHASE II STUDY COMPARING METRONOMIC REGIMENS OF CHEMOTHERAPY IN PATIENTS (PTS) WITH REFRACTORY METASTATIC COLORECTAL CANCER (MCRC)
    Chubenko, V. A.
    Protsenko, S. A.
    Mikhalychenko, T. D.
    Moiseyenko, F. V.
    Brezhnev, N. V.
    Novik, A. V.
    Volkov, N. M.
    Semenov, I. I.
    Moiseyenko, V. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 181 - 182
  • [10] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Masataka Yoshimoto
    Shintaro Takao
    Masaru Hirata
    Yasushi Okamoto
    Sumio Yamashita
    Yoshihiro Kawaguchi
    Makoto Takami
    Hidemi Furusawa
    Satoshi Morita
    Chigusa Abe
    Junichi Sakamoto
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 331 - 338
12345